Extending residence time and stability of peptides by Protected Graft Copolymer (PGC) excipient: GLP-1 example

Pharmaceutical Research

Volumn 29, Issue 1, 2012, Pages 306-318

  Castillo, Gerardo M ^a   Reichstetter, Sandra ^a   Bolotin, Elijah M ^a  

^a PharmaIN Corporation   (United States)

Author keywords

Diabetes; Glucagon like peptide; Peptide excipient; Protected graft copolymer

Indexed keywords

COPOLYMER; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HEMOGLOBIN A1C; PROTECTED GRAFT COPOLYMER; STABILIZING AGENT; UNCLASSIFIED DRUG; DIPEPTIDYL PEPTIDASE IV; EXCIPIENT; FATTY ACID; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INCRETIN; MACROGOL DERIVATIVE; MONOMETHOXYPOLYETHYLENE GLYCOL; PEPTIDE; POLYLYSINE; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG BINDING; DRUG DEGRADATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RESPONSE; DRUG STABILITY; EXCIPIENT COMPATIBILITY; IN VITRO STUDY; IN VIVO STUDY; MEAN RESIDENCE TIME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; ANIMAL; BLOOD; CHEMISTRY; DELAYED RELEASE FORMULATION; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; HUMAN; METABOLISM; PANCREAS ISLET BETA CELL; PROTEIN STABILITY; SPRAGUE DAWLEY RAT; ZUCKER RAT;

ANIMALS; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS; DIPEPTIDYL PEPTIDASE 4; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCIPIENTS; FATTY ACIDS; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INCRETINS; INSULIN-SECRETING CELLS; PEPTIDES; POLYETHYLENE GLYCOLS; POLYLYSINE; PROTEIN STABILITY; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; VENOMS;

EID: 84860593371     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0542-2     Document Type: Article

References (30)

1. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest. 2007;117(1):24-32. (Pubitemid 46048446)
2. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20(6):876-913. (Pubitemid 30647076)
3. Meier JJ, Nauck MA. Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev. 2005;21(2):91-117. (Pubitemid 40467658)
4. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-705. (Pubitemid 46048557)
5. Eng J, Yu J, Rattan S, Yalow RS. Isolation and amino acid sequences of opossum vasoactive intestinal polypeptide and cholecystokinin octapeptide. Proc Natl Acad Sci USA. 1992;89(5):1809-11.
6. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136(8):3585-96.
7. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083-91. (Pubitemid 40616617)
8. Amylin Pharmaceuticals. http://www.rxlist.com/cgi/generic4/byetta-ad.htm. 2008.
9. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47.
10. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30 (6):1487-93. (Pubitemid 46871159)
11. Simonsen L, Holst JJ, Deacon CF. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia. 2006;49(4):706-12. (Pubitemid 43357544)
12. BYETTA. prescribing information [article online, revised june 2008], URL: http://pi.lilly.com/us/byetta-pi.pdf.
13. Huang YS, Chen Z, Chen YQ, Ma GC, Shan JF, Liu W, et al. Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris. J Pept Sci. 2008;14(5):588-95. (Pubitemid 351736454)
14. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes. 2003;52(3):751-9. (Pubitemid 36323583)
15. Lee S, Youn YS, Lee SH, Byun Y, Lee KC. PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/ db mice. Diabetologia. 2006;49(7):1608-11. (Pubitemid 43848097)
16. Pan CQ, Buxton JM, Yung SL, Tom I, Yang L, Chen H, et al. Design of a long acting peptide functioning as both a glucagonlike peptide-1 receptor agonist and a glucagon receptor antagonist. J Biol Chem. 2006;281(18):12506-15. (Pubitemid 43855337)
17. Zhou J, Cai ZH, Li L, Kou C, Gao YF. Preparation and PEGylation of exendin-4 peptide secreted from yeast Pichia pastoris. Eur J Pharm Biopharm. 2009;72(2):412-7.
18. Chae SY, Choi YG, Son S, Jung SY, Lee DS, Lee KC. The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics. J Control Release. 2010;144(1):10-6.
19. Irwin N, O'Harte FP, Gault VA, Green BD, Greer B, Harriott P, et al. GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential. J Med Chem. 2006;49 (3):1047-54. (Pubitemid 43221652)
20. Madsen K, Knudsen LB, Agersoe H, Nielsen PF, Thogersen H, Wilken M, et al. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J Med Chem. 2007;50 (24):6126-32.
21. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab. 2002;283(4):E745-52.
22. Spadaro AC, Draghetta W, Del Lamma SN, Camargo AC, Greene LJ. A convenient manual trinitrobenzenesulfonic acid method for monitoring amino acids and peptides in chromatographic column effluents. Anal Biochem. 1979;96(2):317-21. (Pubitemid 9230571)
23. Bendele A, Seely J, Richey C, Sennello G, Shopp G. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci. 1998;42 (2):152-7. (Pubitemid 28211143)
24. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes. 1999;48(5):1026-34. (Pubitemid 29226349)
25. Lambeir AM, Proost P, Scharpe S, De Meester I. A kinetic study of glucagon-like peptide-1 and glucagon-like peptide-2 truncation by dipeptidyl peptidase IV, in vitro. Biochem Pharmacol. 2002;64 (12):1753-6. (Pubitemid 35351582)
26. Crespel A, De Boisvilliers F, Gros L, Kervran A. Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line. Endocrinology. 1996;137(9):3674-80. (Pubitemid 26284632)
27. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267(11):7402-5.
28. Al-Sabah S, Donnelly D. The primary ligand-binding interaction at the GLP-1 receptor is via the putative helix of the peptide agonists. Protein Pept Lett. 2004;11(1):9-14. (Pubitemid 38345498)
29. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev. 2002;54(4):459-76. (Pubitemid 34615543)
30. Medarova Z, Castillo G, Dai G, Bolotin E, Bogdanov A, Moore A. Noninvasive magnetic resonance imaging of microvascular changes in type 1 diabetes. Diabetes. 2007;56(11):2677-82. (Pubitemid 350044908)